Leading Psychiatrist and TMS practitioner appointed as Medical Advisor to the pioneers of Transcranial Magnetic Stimulation.
Whitland, Wales, UK, 13th October 2015: The Magstim Company Ltd, the innovative and award winning medical device manufacturer, is pleased to announce the appointment of Dr Linda L. Carpenter, M.D as Chief Medical Advisor, with immediate effect.
Dr Carpenter will draw on experience from her roles as Professor of Psychiatry & Human Behaviour (Brown University, Rhode Island) and Chief of the Mood Disorder Program at Butler Hospital (Providence, Rhode Island), in order to provide clinician centric insight into the current and future developments of Magstim’s repetitive Transcranial Magnetic Stimulation (rTMS) technology.
Magstim received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder in the United States in May 2015. This clearance means Magstim can now significantly increase patient and clinician access to its latest rTMS products across the United States.
Speaking of her appointment, Dr Carpenter commented:
“I am very pleased to be taking on the role of Chief Medical Advisor for Magstim. The company is full of talented people with the very highest level of expertise in brain stimulation, and an exceptional dedication to customer service.”
“My extensive experience as a rTMS researcher and psychiatrist delivering clinical TMS therapy to patients with Major Depression for the past 6 years, will be of benefit when introducing this exciting new treatment into mental health care settings. I look forward to providing Magstim with specialist medical guidance in support of the successful introduction of its Rapid2 Therapy System in the US.”
CEO of Magstim, Mr Robin Davies explains:
“Professor Carpenter’s appointment as a practicing clinical psychiatrist brings a wealth of knowledge and experience to Magstim. Her insight into the treatment of Major Depressive Disorder with rTMS is an invaluable asset for Magstim in the development of innovative solutions for clinicians and patients alike.”
Magstim is the pioneer of TMS technology, having established a reputation for developing leading medical devices in the research field for over 25 years. The founding research team behind TMS (Sheffield University, 1985) is actively involved with the company, ensuring that its technology meets and exceeds the needs of today’s researcher and clinician. The company is now committed to build on its experience by bringing its knowledge to the US clinical market.
A video interview with Dr Linda Carpenter is available at: http://www.magstim.com/article/19/professor-linda-carpenter-appointed-chief-medical-advisor-to-magstim
For further information, please visit www.magstim.com
Notes for Editors:
About The Magstim Company
The Magstim Company Limited design, develop and market medical devices used in neuroscience research labs, mental health facilities and the operating theatre. It started trading in 1990 and has won the Queen’s Award for International trade. It has also featured in the ‘Fast Growth 50’ of Welsh Companies.
Magstim provide clinicians and researchers with state-of-the-art stimulation and monitoring equipment to facilitate the assessment, protection and improvement in function of the human nervous system, with effort focused on applications related to magnetic neurological stimulation and intra-operative nerve monitoring. The company has longstanding contacts with key opinion leaders within the clinical and academic sectors.
Magstim is also responsible for the Neurosign range of intra-operative monitors and accessories, which are routinely used by ENT (Ear, Nose and Throat) surgeons to protect vital facial nerves during complex surgery. Please see www.magstim.com and www.neurosignsurgical.com for more information.
Help employers find you! Check out all the jobs and post your resume.
